AS1411-aptamer-functionalized DNA tetrahedron for targeted delivery of vorinostat to suppress gastric cancer progression via ferroptosis induction and epithelial-mesenchymal transition inhibition - Pu
3 hours ago
- #Ferroptosis
- #DNA tetrahedron
- #Gastric cancer
- AS1411-aptamer-functionalized DNA tetrahedron (TAV) delivers vorinostat to target gastric cancer (GC).
- Vorinostat enhances p53 stability by promoting acetylation and inhibiting degradation, leading to dual antitumor effects.
- The drug promotes ferroptosis via the SLC7A11/GPX4 axis and suppresses EMT by downregulating N-cadherin, vimentin, and MMP9.
- Vorinostat also inhibits the PI3K/AKT/mTOR pathway independently of p53, enhancing anti-tumor efficacy.
- TAV demonstrates effective drug delivery, improving vorinostat's solubility and targeting efficiency in GC therapy.
- In vitro and in vivo studies confirm TAV's therapeutic effects and biocompatibility in GC models.